Summary
Boston Scientific Corporation (BSX) filed an 8-K on July 25, 2013, primarily to announce its financial results for the second quarter ended June 30, 2013. The company provided an update on its operations and financial condition through a press release furnished with the filing. Investors should note that this information is considered "furnished" and not "filed," meaning it's not subject to the same liability as formally filed information under Section 18 of the Exchange Act. The filing includes a cautionary statement regarding forward-looking information. BSX highlights that actual results could differ materially from projections due to various risks and uncertainties. These include economic, political, competitive, reimbursement, and regulatory conditions, as well as market acceptance of new products, clinical trial outcomes, and the execution of their business strategy. Investors are advised to consult the company's most recent Annual Report on Form 10-K for a more comprehensive discussion of these risks.
Key Highlights
- 1Boston Scientific announced its Q2 2013 financial results on July 25, 2013.
- 2The 8-K filing includes a press release (Exhibit 99.1) detailing the Q2 financial performance.
- 3The information provided in Item 2.02 is furnished, not filed, and is not subject to Section 18 of the Exchange Act liabilities.
- 4The company included a detailed cautionary statement regarding forward-looking statements.
- 5Potential risks and uncertainties that could impact future results were outlined, affecting business strategy and actual performance.
- 6Investors are directed to review the company's 10-K for a comprehensive list of risks and uncertainties.